

Investor Information**Ticker Symbol**  
**BICX****OTC Marketplace**  
Pink Current**Reporting Status**  
U.S. Reporting: SEC Reporting  
Audited Financials**Authorized Shares**  
525,000,000**Outstanding Shares**  
181,938,501**Recent Share Price**  
\$ .09**Market Value**  
\$ 16,210,720**Chief Executive Officer**  
Brady Granier**Corporate Headquarters**  
2390 East Orangewood Avenue  
Suite 575  
Anaheim, CA 92806

# BioCORRx<sup>®</sup>

BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx<sup>®</sup> Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s).

**Recent BICX Headlines**

Feb 23, 2017

**BioCorRx Provides Preclinical Study Update on BICX101 Development**

Feb 21, 2017

**BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development**

Feb 14, 2017

**BioCorRx (BICX) Update: FDA Results Imminent**

Feb 10, 2017

**BioCorRx Provides Business Update Webcast**

Feb 8, 2017

**BioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction**

Jan 19, 2017

**JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of \$0.09**

Jan 12, 2017

**BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products**

This document may contain forward-looking statements, including information about future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release other than those of historical fact, about an action, event or development, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results to be materially different than those expressed or implied in such statements. StockVest was paid 350,000 restricted shares on 3/01/2017 for 90 days of services.